Tests camrelizumab with ivarmacitinib in children with newly diagnosed Hodgkin lymphoma
Tests camrelizumab plus ivarmacitinib as first treatment in children with Hodgkin lymphoma.
Plain-language title generated from the registry record
Registry title: PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma
Key facts
- Where
- Xuzhou, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 18 years old?
Source: NCT07641010, who can take part
Where in China
- Xuzhou Children's HospitalXuzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Jiao Tong University School of Medicine
- Trial code
- NCT07641010
- Record updated
- 11 June 2026
- Original description
A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphomaRead full original descriptionShow less
A Prospective, Multicenter, Randomized Controlled Clinical Study of Camrelizumab in Combination With Ivarmacitinib as First-line Treatment for Pediatric Classical Hodgkin Lymphoma
A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma
Inclusion: Age 6-18 years, male or female; Histologically confirmed classic Hodgkin lymphoma; Newly diagnosed, previously untreated patients; Subjects must have at least one measurable lesion, defined as: a lymph node lesion with the longest diameter >1.5 cm on CT cross-sectional imaging; or an extranodal lesion with the longest diameter >1.0 cm; ECOG performance status (PS) 0-2; Life expectancy ≥3 months; All screening laboratory tests must be performed as required by the protocol and within 7 days prior to enrollment. The laboratory values obtained at screening must meet the following criteria:; Hematology (without blood transfusion, G-CSF, or medication to correct abnormalities within 14 days prior to screening):; Hemoglobin (Hb) ≥70 g/L; Absolute neutrophil count (ANC) ≥0.5×10⁹/L; Platelet count (PLT) ≥30×10⁹/L; Biochemistry:; Direct bilirubin (DBIL) <2 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN; Serum creatinine clearance ≥40 mL/min; The patient or his/her legal guardian has signed the informed consent form (ICF) and voluntarily agrees to participate in this study.
Exclusion: Prior anti-tumor therapy for classic Hodgkin lymphoma (cHL); Inability to swallow oral medication, or any other factor affecting oral drug administration and absorption; Use of immunosuppressive agents, including systemic corticosteroids, within 14 days prior to study drug administration (use of ≤10 mg/day prednisone or equivalent is permitted); Presence of any active, known, or suspected autoimmune disease (subjects who are in a stable condition and do not require systemic immunosuppressive therapy are permitted to enroll); History of other malignancies within the past 5 years; Any arterial thromboembolic event within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack; Active hepatitis B or hepatitis C infection; History of stroke or intracranial hemorrhage within the past 6 months; Known history of human immunodeficiency virus (HIV) positivity; Histopathologically confirmed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL); Severe cardiac dysfunction with ejection fraction (EF) <50%, or severe cardiac arrhythmia; Patients with central nervous system (CNS) involvement by lymphoma.